Page 142 - IJB-10-3

International Journal of Bioprinting New challenges in liver tissue engineering

liver disease: analysis of data from two prospective cohort 25. Björnsson ES, Gunnarsson BI, Gröndal G, et al. Risk of drug-
studies. BMJ. 2010;340(7747):634. induced liver injury from tumor necrosis factor antagonists.
doi: 10.1136/bmj.c1240 Clin Gastroenterol Hepatol. 2015;13(3):602-608.
doi: 10.1016/j.cgh.2014.07.062
13. Bataller R, Cabezas J, Aller R, et al. Enfermedad hepática
por alcohol. Guías de práctica clínica. Documento de 26. EASL. EASL Clinical Practice Guidelines: drug-induced
consenso auspiciado por la AEEH. Gastroenterol Hepatol. liver injury. J Hepatol. 2019;70(6):1222-1261.
2019;42(10):657-676. doi: 10.1016/j.jhep.2019.02.014
doi: 10.1016/j.gastrohep.2019.09.006 27. Anand SK, Caputo M, Xia Y, et al. Inhibition of MAP4K4
14. Bhatia SN, Underhill GH, Zaret KS, Fox IJ. Cell and tissue signaling initiates metabolic reprogramming to
engineering for liver disease. Sci Transl Med. 2014;6(245). protect hepatocytes from lipotoxic damage. J Lipid Res.
doi: 10.1126/scitranslmed.3005975 2022;63(7):100238.
doi: 10.1016/j.jlr.2022.100238
15. Pelechá M, Villanueva-Bádenas E, Timor-López E, Donato
MT, Tolosa L. Cell models and omics techniques for the 28. Pareja E, Gómez-Lechón MJ, Tolosa L. Induced pluripotent
study of nonalcoholic fatty liver disease: focusing on stem stem cells for the treatment of liver diseases: challenges and
cell-derived cell models. Antioxidants. 2021;11(1):86. perspectives from a clinical viewpoint. Ann Transl Med.
doi: 10.3390/antiox11010086 2020;8(8):566-566.
doi: 10.21037/atm.2020.02.164
16. Ströbel S, Kostadinova R, Fiaschetti-Egli K, et al. A 3D
primary human cell-based in vitro model of non-alcoholic 29. Adam R, Karam V, Delvart V, et al. Evolution of indications
steatohepatitis for efficacy testing of clinical drug candidates. and results of liver transplantation in Europe. A report from
Sci Rep. 2021;11(1):22765. the European Liver Transplant Registry (ELTR). J Hepatol.
doi: 10.1038/s41598-021-01951-7 2012;57(3):675-688.
doi: 10.1016/j.jhep.2012.04.015
17. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell
activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397-411. 30. Dutkowski P, Linecker M, DeOliveira ML, Müllhaupt B,
doi: 10.1038/nrgastro.2017.38 Clavien PA. Challenges to liver transplantation and strategies
to improve outcomes. Gastroenterology. 2015;148(2):307-323.
18. EASL. EASL-EASD-EASO Clinical Practice Guidelines for doi: 10.1053/j.gastro.2014.08.045
the management of non-alcoholic fatty liver disease. Obes 31. Bizzaro, Russo, Burra. New perspectives in liver
Facts. 2016;9(2):65-90. transplantation: from regeneration to bioengineering.
doi: 10.1159/000443344
Bioengineering. 2019;6(3):81.
19. Diehl AM, Day C. Cause, pathogenesis, and treatment doi: 10.3390/bioengineering6030081
of nonalcoholic steatohepatitis. N Engl J Med. 32. Smets F, Najimi M, Sokal EM. Cell transplantation in the
2017;377(21):2063-2072. treatment of liver diseases. Pediatr Transplant. 2008;12(1):6-13.
doi: 10.1056/NEJMra1503519 doi: 10.1111/j.1399-3046.2007.00788.x
20. Arzumanyan A, Reis HMGPV, Feitelson MA. Pathogenic 33. Lysy PA, Najimi M, Stéphenne X, Bourgois A, Smets F, Sokal
mechanisms in HBV- and HCV-associated hepatocellular EM. Liver cell transplantation for Crigler-Najjar syndrome
carcinoma. Nat Rev Cancer. 2013;13(2):123-135. type I: update and perspectives. World J Gastroenterol.
doi: 10.1038/nrc3449 2008;14(22):3464.
21. Ray G. Management of liver diseases: current perspectives. doi: 10.3748/wjg.14.3464
World J Gastroenterol. 2022;28(40):5818-5826. 34. van de Kerkhove MP, Hoekstra R, Chamuleau RAFM, van
doi: 10.3748/wjg.v28.i40.5818 Gulik TM. Clinical application of bioartificial liver support
22. Dhanasekaran R, Bandoh S, Roberts LR. Molecular systems. Ann Surg. 2004;240(2):216-230.
pathogenesis of hepatocellular carcinoma and impact of doi: 10.1097/01.sla.0000132986.75257.19
therapeutic advances. F1000Res. 2016;5:879. 35. Gebhardt R, Matz-Soja M. Liver zonation: novel aspects
doi: 10.12688/f1000research.6946.1 of its regulation and its impact on homeostasis. World J
23. Ruff SM, Manne A, Cloyd JM, Dillhoff M, Ejaz A, Pawlik Gastroenterol. 2014;20(26):8491.
TM. Current landscape of immune checkpoint inhibitor doi: 10.3748/wjg.v20.i26.8491
therapy for hepatocellular carcinoma. Curr Oncol. 2023;30(6): 36. Panday R, Monckton CP, Khetani SR. The role of liver
5863-5875. zonation in physiology, regeneration, and disease. Semin
doi: 10.3390/curroncol30060439 Liver Dis. 2022;42(01):001-016.
doi: 10.1055/s-0041-1742279
24. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev
Drug Discov. 2005;4(6):489-499. 37. Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol.
doi: 10.1038/nrd1750 2017;27(21):R1147-R1151.

Volume 10 Issue 3 (2024) 134 doi: 10.36922/ijb.2706